

Subject: CARES Act - DARPA COVID-19 Response Appropriation Title: Various Appropriations	DoD Serial Number: FY 20-23 IR
	Includes Transfer? Yes

Component Serial Number: Line Item a	(Amounts in Thousands of Dollars)							
	Program Base Reflecting Congressional Action		Program Previously Approved by Sec Def		Reprogramming Action		Revised Program	
	Quantity	Amount	Quantity	Amount	Quantity	Amount	Quantity	Amount
	b	c	d	e	f	g	h	i

This reprogramming transfers \$113.0 million from the Defense Health Program, 20/20, appropriation, appropriated in Title III of Division B of Public Law 116-136, the CARES Act, to the Research, Development, Test and Evaluation, Defense Wide, 20/21, appropriation, in accordance with Section 13001 of Title III of Division B of Public Law 116-136, the CARES Act. The reprogramming is necessary for expenses to prevent, prepare for, or respond to coronavirus. This reprogramming action meets all administrative and legal requirements, and none of the items have been previously denied by the Congress.

<u>FY 2020 REPROGRAMMING INCREASE:</u>	<u>+113,000</u>
<u>DEFENSE-WIDE</u>	<u>+113,000</u>
<u>Research, Development, Test, and Evaluation, Defense-Wide, 20/21</u>	<u>+113,000</u>
<u>Budget Activity 01: Basic Research</u>	
0601101E Defense Research Sciences	
432,284	432,284
	+304
	432,588

Explanation: Funds are required to apply artificial intelligence (AI)-based models to rapidly screen, prioritize and test Food and Drug Administration (FDA)-approved therapeutics for new COVID-19 drug candidates. Without this funding, such rapid AI-enabled screening capabilities cannot be established in time to respond to the current crisis. Congress appropriated \$3.8 billion in Defense Health Program funding to prevent, prepare for, and respond to coronavirus, domestically or internationally. This action does not change the purpose for which the funds were originally appropriated. This is a congressional special interest item. This is a Division B Title III, CARES Act requirement.

0601117E Basic Operational Medical Research Science	
54,122	54,122
	+5,000
	59,122

Explanation: Funds are required to identify Food and Drug Administration (FDA)-approved drugs that could be repurposed as effective treatments for COVID-19. Specifically, drugs are being identified that could disrupt the virus interaction networks with human cells. Without this funding, it will not be possible to identify FDA-approved drugs in time to respond to the current crisis. Congress appropriated \$3.8 billion in Defense Health Program funding to prevent, prepare for, and respond to coronavirus, domestically or internationally. This action does not change the purpose for which the funds were originally appropriated. This is a congressional special interest item. This is a Division B Title III, CARES Act requirement.

Approved (Signature and Date)

Subject: CARES Act, DARPA COVID-19 Response						DoD Serial Number: FY 20-23 IR			
Appropriation Title: Various Appropriations						Includes Transfer? Yes			
Component Serial Number:		<i>(Amounts in Thousands of Dollars)</i>							
		Program Base Reflecting Congressional Action		Program Previously Approved by Sec Def		Reprogramming Action		Revised Program	
Line Item		Quantity	Amount	Quantity	Amount	Quantity	Amount	Quantity	Amount
a		b	c	d	e	f	g	h	i
<u>Budget Activity 02: Applied Research</u>									
0602115E Biomedical Technology									
		92,771		92,771		+52,000		144,771	
<u>Explanation:</u>									
Funds are required to prevent, diagnose, and treat COVID-19. Funding is needed to run: 1) a Phase II human trial to test COVID-19 Ribonucleic Acid (RNA) vaccine efficacy in 500-1000 DoD personnel, and 2) Phase I human trials to test safety of novel antibody-based COVID-19 treatments. Funding also is needed to gain FDA approval of tests that may be able to perform early, pre-symptomatic and asymptomatic diagnosis of COVID-19 patients and make these tests available through scaled up manufacturing. Without additional funding, these measures to prevent, diagnose and treat COVID-19 would not be able proceed quickly enough to have an impact for this pandemic. Congress appropriated \$3.8 billion in Defense Health Program funding to prevent, prepare for, and respond to coronavirus, domestically or internationally. This action does not change the purpose for which the funds were originally appropriated. This is a congressional special interest item. This is a Division B Title III, CARES Act requirement.									
0602303E Information & Communications Technology									
		428,556		428,556		+619		429,175	
<u>Explanation:</u>									
Funds are required to apply artificial intelligence (AI)-based models to rapidly screen, prioritize and test Food and Drug Administration (FDA)-approved therapeutics for new COVID-19 drug candidates. Without this funding, such rapid AI-enabled screening capabilities cannot be established in time to respond to the current crisis. Congress appropriated \$3.8 billion in Defense Health Program funding to prevent, prepare for, and respond to coronavirus, domestically or internationally. This action does not change the purpose for which the funds were originally appropriated. This is a congressional special interest item. This is a Division B Title III, CARES Act requirement.									
0602383E Biological Warfare Defense									
		34,588		34,588		+2,000		36,588	
<u>Explanation:</u>									
Funds are required to rapidly develop and field a potential capability to detect airborne Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and enable persistent, broad-scale environmental screening for contagion, such as in airports, mass transportation hubs and public areas where community transmission control is critical. Without additional funding, development would not be available in time to respond to the current crisis. Congress appropriated \$3.8 billion in Defense Health Program funding to prevent, prepare for, and respond to coronavirus, domestically or internationally. This action does not change the purpose for which the funds were originally									

Subject: CARES Act, DARPA COVID-19 Response	DoD Serial Number: FY 20-23 IR
Appropriation Title: Various Appropriations	
Includes Transfer? Yes	

Component Serial Number:	<i>(Amounts in Thousands of Dollars)</i>							
	Program Base Reflecting Congressional Action		Program Previously Approved by Sec Def		Reprogramming Action		Revised Program	
Line Item	Quantity	Amount	Quantity	Amount	Quantity	Amount	Quantity	Amount
a	b	c	d	e	f	g	h	i

appropriated. This is a congressional special interest item. This is a Division B Title III, CARES Act requirement.

0602715E Materials and Biological Technology	214,976	214,976	+53,077	268,053
--	---------	---------	----------------	---------

Explanation: Funds are required to test ultra-sensitive methods for diagnosing COVID-19, develop U.S. sourced production capabilities for chemical precursors needed to produce pharmaceuticals critical to SARS-CoV-2/COVID-19, and assess the efficacy of Food and Drug Administration (FDA)-approved therapeutic drug candidates for treatment of COVID-19. Drug candidates are being rapidly screened for safety and efficacy screens using human lung-on-a-chip technology. There are no other organizations addressing the vulnerabilities in the U.S. supply chain for pharmaceutical precursors, which will impact not only pharmaceuticals to address SARS-CoV-2/COVID-19, but also our medical supply chain, generally. Without additional funding for diagnosis and treatment of COVID-19, medical professionals will not be able to provide the best quality of care to patients. Congress appropriated \$3.8 billion in Defense Health Program funding to prevent, prepare for, and respond to coronavirus, domestically or internationally. This action does not change the purpose for which the funds were originally appropriated. This is a congressional special interest item. This is a Division B Title III, CARES Act requirement.

<u>FY 2020 REPROGRAMMING DECREASE:</u>		<u>-113,000</u>		
<u>Defense Health Program, 20/20</u>		<u>-113,000</u>		
<u>Budget Activity 01: Operation and Maintenance</u>	36,013,452	36,013,452	<u>-113,000</u>	35,900,452

Explanation: Funds are available because they were appropriated as part of the FY 2020 CARES Act, \$3.8 billion in Defense Health Program funding to prevent, prepare for, and respond to coronavirus, domestically or internationally. Upon further analysis, excess funding is available in Consolidated Health Support (Budget Activity Group 3) based on initial spend plan distribution. Funds are available due to reduced requirements for expansion of medical facilities. This action does not change the purpose for which the funds were originally appropriated. This is a congressional special interest item. This is Division B Title III, CARES Act funding.